CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
P/B ratio for CytomX Therapeutics, Inc. (CTMX)
P/B ratio as of 2023: -2.41
According to CytomX Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -2.41. At the end of 2022 the company had a P/B ratio of -1.23.
P/B ratio history for CytomX Therapeutics, Inc. from 2013 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -2.41 |
| 2022 | -1.23 |
| 2021 | 3.11 |
| 2020 | 6.07 |
| 2019 | 7.37 |
| 2018 | 4.81 |
| 2017 | 11.23 |
| 2016 | 5.07 |
| 2015 | 1.42 |
| 2014 | -5.74 |
| 2013 | -10.17 |